Overall Status

Active, not recruiting (2)

Completed (1)

Phase

phase 1 (1)

phase 2 (1)

phase 3 (1)

Sponsor

National Cancer Institute (NCI) (2)

Mayo Clinic (1)

Collaborator

Celgene Corporation (1)

National Cancer Institute (NCI) (1)

Intervention

rituximab (3)

laboratory biomarker analysis (2)

lenalidomide (2)

ibrutinib (1)

pharmacological study (1)

quality-of-life assessment (1)

yttrium y-90 ibritumomab tiuxetan (1)

Study Documents

Intervention Type

biological (3)

other (3)

drug (2)

radiation (1)

Funder Type

NIH (2)

Other (1)

Study Type

Interventional (3)

ann arbor stage ii grade 2 contiguous follicular lymphoma

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma, Ann

Active, not recruiting

Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma
+11 more

Ibrutinib
+4 more

Washington, District of Columbia
+6 more

Feb 2, 2023

Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma, Ann

Completed

Has Results

Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma
+11 more

Laboratory Biomarker Analysis
+2 more

Mountain View, California
+90 more

Aug 3, 2022

Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2 Follicular Lymphoma, Ann Arbor Stage II Grade 1

Active, not recruiting

Ann Arbor Stage I Grade 1 Follicular Lymphoma
+9 more

Quality-of-Life Assessment
+2 more

Rochester, Minnesota

Mayo Clinic in Rochester

Feb 3, 2022